BRIEF-Acceleron announces top-line results from dart phase 2 study of dalantercept By: Reuters: Company News June 12, 2017 at 16:42 PM EDT * Acceleron announces top-line results from dart phase 2 study of dalantercept in advanced renal cell carcinoma Read More >> Related Stocks: Acceleron Pharma